FIELD: medicine.
SUBSTANCE: binding molecule represents a CD45RO and CD45RB chimeric antibody. The molecule contains two domains with consistent hypervariable sites CDR1, CDR2 and CDR3, and CDR1', CDR2' and CDR3', CDR1 has amino acid sequence NYIIH, CDR2 has amino acid sequence YFNPYNHGTKYNEKFKG, and CDR3 has amino acid sequence SGPYAWFDT. CDR1' has amino acid sequence RASQNIGTSIQ, CDR2' has amino acid sequence SSSESIS, and CDR3' has amino acid sequence QQSNTWPFT. Related coding polynucleotide is described.
EFFECT: use of the invention allows to induce immunosuppression, to inhibit T-cell response and primary lymphocyte reaction in the mixed culture, to prolong survival time in mice with severe combined immunodeficiency SCID.
6 cl, 5 dwg, 2 tbl, 8 ex
Title | Year | Author | Number |
---|---|---|---|
THERAPEUTIC BINDING MOLECULES | 2002 |
|
RU2328506C2 |
HUMAN MONOCLONAL ANTIBODIES TO HUMAN INTERLEUKINE-4 (hIL-4) | 2005 |
|
RU2382049C2 |
ANTI-IL-5 ANTIBODIES | 2017 |
|
RU2758008C2 |
MONOCLONAL ANTIBODIES TO INTERLEUKIN-31 FOR VETERINARY USE | 2019 |
|
RU2795411C2 |
ANTIBODIES TO CHIMERIC ANTIGEN RECEPTORS DERIVED FROM 4G7 | 2020 |
|
RU2826051C2 |
ANTI-SIRPα ANTIBODY AND USE THEREOF | 2021 |
|
RU2822496C1 |
ANTIBODY AGENTS SPECIFIC TO HUMAN CD19, AND THEIR APPLICATIONS | 2016 |
|
RU2773317C2 |
MONOCLONAL ANTIBODIES AGAINST HUMAN TIM-3 | 2019 |
|
RU2777336C1 |
ANTI-C5 ANTIBODIES AND THEIR USE | 2018 |
|
RU2774716C2 |
PEPTIDE VACCINES AGAINST INTERLEUKIN-31 | 2019 |
|
RU2786441C2 |
Authors
Dates
2010-12-10—Published
2002-02-11—Filed